A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk
H. Dean Hosgood III
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorMark P. Purdue
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorSophia S. Wang
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Division of Etiology, Department of Population Sciences, City of Hope, Duarte, CA
Search for more papers by this authorTongzhang Zheng
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorLindsay M. Morton
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorQing Lan
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorIdan Menashe
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorYawei Zhang
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorJames R. Cerhan
Mayo Clinic, College of Medicine, Rochester, MN, USA
Search for more papers by this authorAndrew Grulich
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
Search for more papers by this authorWendy Cozen
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
Search for more papers by this authorMeredith Yeager
Core Genotyping Facility, Advanced Technology Center, National Cancer Institute, NIH, DHHS, Gaithersburg, MD, USA
Search for more papers by this authorTheodore R. Holford
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorClaire M. Vajdic
Prince of Wales Clinical School and Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia
Search for more papers by this authorScott Davis
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
Search for more papers by this authorBrian Leaderer
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorAnne Kricker
School of Public Health, The University of Sydney, Sydney, NSW, Australia
Search for more papers by this authorMaryjean Schenk
Department of Family Medicine and Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
Search for more papers by this authorShelia H. Zahm
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorNilanjan Chatterjee
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorStephen J. Chanock
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorNathaniel Rothman
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorPatricia Hartge
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorBruce Armstrong
School of Public Health, The University of Sydney, Sydney, NSW, Australia
Search for more papers by this authorH. Dean Hosgood III
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorMark P. Purdue
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorSophia S. Wang
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Division of Etiology, Department of Population Sciences, City of Hope, Duarte, CA
Search for more papers by this authorTongzhang Zheng
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorLindsay M. Morton
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorQing Lan
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorIdan Menashe
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorYawei Zhang
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorJames R. Cerhan
Mayo Clinic, College of Medicine, Rochester, MN, USA
Search for more papers by this authorAndrew Grulich
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
Search for more papers by this authorWendy Cozen
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
Search for more papers by this authorMeredith Yeager
Core Genotyping Facility, Advanced Technology Center, National Cancer Institute, NIH, DHHS, Gaithersburg, MD, USA
Search for more papers by this authorTheodore R. Holford
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorClaire M. Vajdic
Prince of Wales Clinical School and Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia
Search for more papers by this authorScott Davis
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
Search for more papers by this authorBrian Leaderer
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT
Search for more papers by this authorAnne Kricker
School of Public Health, The University of Sydney, Sydney, NSW, Australia
Search for more papers by this authorMaryjean Schenk
Department of Family Medicine and Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
Search for more papers by this authorShelia H. Zahm
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorNilanjan Chatterjee
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorStephen J. Chanock
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorNathaniel Rothman
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorPatricia Hartge
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD
Search for more papers by this authorBruce Armstrong
School of Public Health, The University of Sydney, Sydney, NSW, Australia
Search for more papers by this authorSummary
Genetic variation in immune-related genes may play a role in the development of non-Hodgkin lymphoma (NHL). To test the hypothesis that innate immunity polymorphisms may be associated with NHL risk, we genotyped 144 tag single nucleotide polymorphisms (tagSNPs) capturing common genetic variation within 12 innate immunity gene regions in three independent population-based case-control studies (1946 cases and 1808 controls). Gene-based analyses found IL1RN to be associated with NHL risk (minP = 0·03); specifically, IL1RN rs2637988 was associated with an increased risk of NHL (per-allele odds ratio = 1·15, 95% confidence interval = 1·05–1·27; Ptrend = 0·003), which was consistent across study, subtype, and gender. FCGR2A was also associated with a decreased risk of the follicular lymphoma NHL subtype (minP = 0·03). Our findings suggest that genetic variation in IL1RN and FCGR2A may play a role in lymphomagenesis. Given that conflicting results have been reported regarding the association between IL1RN SNPs and NHL risk, a larger number of innate immunity genes with sufficient genomic coverage should be evaluated systematically across many studies.
Supporting Information
Table I. Subject characteristics, by study.
Table II. Characteristics of innate immunity tagSNPs genotyped.
Table III. Odds ratios and 95% confidence intervals for innate immunity tagSNPs and risk of NHL, adjusted for age, race, gender, and study site, by study.
Table IV. Odds ratios and 95% confidence intervals for innate immunity tagSNPs and risk of NHL subtypes, adjusted for age, race, gender, and study site.
| Filename | Description |
|---|---|
| BJH_8518_sm_tableS1-S4.xls659 KB | Supporting info item |
| BJH_8518_sm_tablelegends.doc22.5 KB | Supporting info item |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Andrie, E., Michos, A., Kalampoki, V., Pourtsidis, A., Moschovi, M., Polychronopoulou, S., Athanasiadou-Piperopoulou, F., Kalmanti, M., Hatzakis, A., Paraskevis, D., Nieters, A. & Petridou, E.T. (2009) Genetic variants in immunoregulatory genes and risk for childhood lymphomas. European Journal of Haematology, 83, 334–342.
- Asano, K., Matsushita, T., Umeno, J., Hosono, N., Takahashi, A., Kawaguchi, T., Matsumoto, T., Matsui, T., Kakuta, Y., Kinouchi, Y., Shimosegawa, T., Hosokawa, M., Arimura, Y., Shinomura, Y., Kiyohara, Y., Tsunoda, T., Kamatani, N., Iida, M., Nakamura, Y. & Kubo, M. (2009) A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nature Genetics, 41, 1325–1329.
- Bastion, Y., Sebban, C., Berger, F., Felman, P., Salles, G., Dumontet, C., Bryon, P.A. & Coiffier, B. (1997) Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. Journal of Clinical Oncology, 15, 1587–1594.
- Bhatti, P., Sigurdson, A.J., Wang, S.S., Chen, J., Rothman, N., Hartge, P., Bergen, A.W. & Landi, M.T. (2005) Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiology, Biomarkers and Prevention, 14, 2449–2453.
- Bonizzi, G. & Karin, M. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends in Immunology, 25, 280–288.
- Bournazos, S., Woof, J.M., Hart, S.P. & Dransfield, I. (2009) Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clinical & Experimental Immunology, 157, 244–254.
- Carlson, C.S., Eberle, M.A., Rieder, M.J., Yi, Q., Kruglyak, L. & Nickerson, D.A. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. American Journal of Human Genetics, 74, 106–120.
- Chatterjee, N., Hartge, P., Cerhan, J.R., Cozen, W., Davis, S., Ishibe, N., Colt, J., Goldin, L. & Severson, R.K. (2004) Risk of non-Hodgkin’s lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiology, Biomarkers and Prevention, 13, 1415–1421.
- Chen, B.E., Sakoda, L.C., Hsing, A.W. & Rosenberg, P.S. (2006) Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. Genetic Epidemiology, 30, 495–507.
- Elahi, M.M., McMillan, D.C., McArdle, C.S., Angerson, W.J., Soukop, M., Johnstone, J. & Sattar, N. (2005) The systemic inflammatory response predicts overall and cancer specific survival in patients with malignant lymphoma. Medical Science Monitor, 11, CR75–CR78.
- Forrest, M.S., Skibola, C.F., Lightfoot, T.J., Bracci, P.M., Willett, E.V., Smith, M.T., Holly, E.A. & Roman, E. (2006) Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. British Journal of Haematology, 134, 180–183.
- Ghosh, S., May, M.J. & Kopp, E.B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology, 16, 225–260.
- Hoeft, B., Becker, N., Deeg, E., Beckmann, L. & Nieters, A. (2008) Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma. Cancer Causes and Control, 19, 163–173.
- Hofmann, S.R., Ettinger, R., Zhou, Y.J., Gadina, M., Lipsky, P., Siegel, R., Candotti, F. & O’Shea, J.J. (2002) Cytokines and their role in lymphoid development, differentiation and homeostasis. Current Opinion in Allergy and Clinical Immunology, 2, 495–506.
- Huang, B.E., Amos, C.I. & Lin, D.Y. (2007) Detecting haplotype effects in genomewide association studies. Genetic Epidemiology, 31, 803–812.
- Kabelitz, D. & Medzhitov, R. (2007) Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Current Opinion in Immunology, 19, 1–3.
- Karassa, F.B., Trikalinos, T.A. & Ioannidis, J.P. (2004) The role of FcgammaRIIA and IIIA polymorphisms in autoimmune diseases. Biomedicine and Pharmacotherapy, 58, 286–291.
- Koene, H.R., Kleijer, M., Algra, J., Roos, D., von dem Borne, A.E. & de Haas, M. (1997) Fcgamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell fcgamma RIIIa, independently of the Fcgamma RIIIa-48L/R/H phenotype. Blood, 90, 1109–1114.
- Lan, Q., Zheng, T., Rothman, N., Zhang, Y., Wang, S.S., Shen, M., Berndt, S.I., Zahm, S.H., Holford, T.R., Leaderer, B., Yeager, M., Welch, R., Boyle, P., Zhang, B., Zou, K., Zhu, Y. & Chanock, S. (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood, 107, 4101–4108.
- Langer, H.F. & Chavakis, T. (2009) Leukocyte ΓÇô endothelial interactions in inflammation. Journal of Cellular and Molecular Medicine, 13, 1211–1220.
- Lehrnbecher, T., Foster, C.B., Zhu, S., Leitman, S.F., Goldin, L.R., Huppi, K. & Chanock, S.J. (1999) Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood, 94, 4220–4232.
- Lucey, D.R., Clerici, M. & Shearer, G.M. (1996) Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clinical Microbiology Reviews, 9, 532–562.
- Mantovani, A., Schioppa, T., Porta, C., Allavena, P. & Sica, A. (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer and Metastasis Reviews, 25, 315–322.
- Maxwell, K.F., Powell, M.S., Hulett, M.D., Barton, P.A., McKenzie, I.F.C., Garrett, T.P.J. & Hogarth, P.M. (1999) Crystal structure of the human leukocyte Fc receptor, Fc[gamma]RIIa. Nature Structural & Molecular Biology, 6, 437–442.
- Morton, L.M., Turner, J.J., Cerhan, J.R., Linet, M.S., Treseler, P.A., Clarke, C.A., Jack, A., Cozen, W., Maynadie, M., Spinelli, J.J., Costantini, A.S., Rudiger, T., Scarpa, A., Zheng, T. & Weisenburger, D.D. (2007) Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 110, 695–708.
- Muller, A.M., Ihorst, G., Mertelsmann, R. & Engelhardt, M. (2005) Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Annals of Hematology, 84, 1–12.
- Parker, D., Alison, D.L., Barnard, D.L., Child, J.A., Dovey, G., Farish, J., Norfolk, D.R., O’Brien, C.J., Parapia, L.A. & Sharp, J. (1994) Prognosis in low grade non-Hodgkin’s lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level. Hematological Oncology, 12, 15–27.
- Purdue, M.P., Lan, Q., Kricker, A., Grulich, A.E., Vajdic, C.M., Turner, J., Whitby, D., Chanock, S., Rothman, N. & Armstrong, B.K. (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis, 28, 704–712.
- Rollinson, S., Levene, A.P., Mensah, F.K., Roddam, P.L., Allan, J.M., Diss, T.C., Roman, E., Jack, A., MacLennan, K., Dixon, M.F. & Morgan, G.J. (2003) Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood, 102, 1007–1011.
- Rothman, N., Skibola, C.F., Wang, S.S., Morgan, G., Lan, Q., Smith, M.T., Spinelli, J.J., Willett, E., De Sanjose S., Cocco, P., Berndt, S.I., Brennan, P., Brooks-Wilson, A., Wacholder, S., Becker, N., Hartge, P., Zheng, T., Roman, E., Holly, E.A., Boffetta, P., Armstrong, B., Cozen, W., Linet, M., Bosch, F.X., Ennas, M.G., Holford, T.R., Gallagher, R.P., Rollinson, S., Bracci, P.M., Cerhan, J.R., Whitby, D., Moore, P.S., Leaderer, B., Lai, A., Spink, C., Davis, S., Bosch, R., Scarpa, A., Zhang, Y., Severson, R.K., Yeager, M., Chanock, S. & Nieters, A. (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. The Lancet Oncology, 7, 27–38.
- Salmon, J.E., Millard, S., Schachter, L.A., Arnett, F.C., Ginzler, E.M., Gourley, M.F., Ramsey-Goldman, R., Peterson, M.G. & Kimberly, R.P. (1996) Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. Journal of Clinical Investigation, 97, 1348–1354.
- Santtila, S., Savinainen, K. & Hurme, M. (1998) Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scandinavian Journal of Immunology, 47, 195–198.
- Schaid, D.J., Rowland, C.M., Tines, D.E., Jacobson, R.M. & Poland, G.A. (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. American Journal of Human Genetics, 70, 425–434.
- Skibola, C.F., Bracci, P.M., Nieters, A., Brooks-Wilson, A., de Sanjosé, S., Hughes, A.M., Cerhan, J.R., Skibola, D.R., Purdue, M., Kane, E., Lan, Q., Foretova, L., Schenk, M., Spinelli, J.J., Slager, S.L., De Roos, A.J., Smith, M.T., Roman, E., Cozen, W., Boffetta, P., Kricker, A., Zheng, T., Lightfoot, T., Cocco, P., Benavente, Y., Zhang, Y., Hartge, P., Linet, M.S., Becker, N., Brennan, P., Zhang, L., Armstrong, B., Smith, A., Shiao, R., Novak, A.J., Maynadie, M., Chanock, S.J., Staines, A., Holford, T.R., Holly, E.A., Rothman, N. & Wang, S.S. (2010) Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. American Journal of Epidemiology, 171, 267–276.
- Wang, S.S., Cerhan, J.R., Hartge, P., Davis, S., Cozen, W., Severson, R.K., Chatterjee, N., Yeager, M., Chanock, S.J. & Rothman, N. (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-hodgkin lymphoma. Cancer Research, 66, 9771–9780.
- Wang, S.S., Slager, S.L., Brennan, P., Holly, E.A., De Sanjose, S., Bernstein, L., Boffetta, P., Cerhan, J.R., Maynadie, M., Spinelli, J.J., Chiu, B.C., Cocco, P.L., Mensah, F., Zhang, Y., Nieters, A., Dal, M.L., Bracci, P.M., Costantini, A.S., Vineis, P., Severson, R.K., Roman, E., Cozen, W., Weisenburger, D., Davis, S., Franceschi, S., La, V.C., Foretova, L., Becker, N., Staines, A., Vornanen, M., Zheng, T. & Hartge, P. (2007) Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 109, 3479–3488.
- Wang, S.S., Purdue, M.P., Cerhan, J.R., Zheng, T., Menashe, I., Armstrong, B.K., Lan, Q., Hartge, P., Kricker, A., Zhang, Y., Morton, L.M., Vajdic, C.M., Holford, T.R., Severson, R.K., Grulich, A., Leaderer, B.P., Davis, S., Cozen, W., Yeager, M., Chanock, S.J., Chatterjee, N. & Rothman, N. (2009) Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS ONE, 4, e5360.
- Warmerdam, P.A., van de Winkel, J.G., Gosselin, E.J. & Capel, P.J. (1990) Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). The Journal of Experimental Medicine, 172, 19–25.
- Warmerdam, P.A., van de Winkel, J.G., Vlug, A., Westerdaal, N.A. & Capel, P.J. (1991) A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. The Journal of Immunology, 147, 1338–1343.
- Witkin, S.S., Gerber, S. & Ledger, W.J. (2002) Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clinical Infectious Diseases, 34, 204–209.
- Wu, M.S., Shun, C.T., Huang, S.P., Cheng, A.L., Chen, L.T. & Lin, J.T. (2004) Effect of interleukin-1 beta and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica, 89, 1015–1017.
Citing Literature
